Nuvilex (NASDAQ:PMCB) Releases Quarterly Earnings Results

Nuvilex (NASDAQ:PMCB) posted its quarterly earnings results on Tuesday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Nuvilex Stock Performance

Shares of NASDAQ PMCB traded down $0.01 during trading hours on Tuesday, hitting $0.69. The company’s stock had a trading volume of 76,859 shares, compared to its average volume of 238,981. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.73. The business has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $0.87. The stock has a market cap of $7.40 million, a price-to-earnings ratio of -0.50 and a beta of 0.33.

Insider Activity

In other news, CEO Joshua Silverman purchased 40,000 shares of Nuvilex stock in a transaction that occurred on Wednesday, January 7th. The shares were bought at an average cost of $0.83 per share, with a total value of $33,200.00. Following the completion of the purchase, the chief executive officer directly owned 416,250 shares in the company, valued at approximately $345,487.50. This trade represents a 10.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have bought a total of 110,000 shares of company stock worth $89,000 in the last 90 days. 10.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PMCB has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Nuvilex to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.